Digestive diseases and sciences · 2006
Long-term effectiveness of azathioprine in IBD beyond 4 years: a European multicenter study in 1176 patients.
Сравнительное исследованиеСтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Holtmann Martin H, Krummenauer Frank, Claas Christina, Kremeyer Kristina, Lorenz Dirk, Rainer Olivia, Vogel Iris, Böcker Ulrich, Böhm Stephan, Büning Carsten, Duchmann Rainer, Gerken Guido, Herfarth Hans, Lügering Norbert, Kruis Wolfgang, Reinshagen Max, Schmidt Jan, Stallmach Andreas, Stein Jürgen, Sturm Andreas, Galle Peter R, Hommes Daan W, D'Haens Geert, Rutgeerts Paul, Neurath Markus F
Аннотация
In Crohn's disease the optimal duration of azathioprine treatment is still controversial and for ulcerative colitis only limited data are available to support its efficacy. Charts of 1176 patients with IBD from 16 European centers were analyzed. Flare incidences and steroid dosages were assessed for the time before and during treatment and after discontinuation. Within the first 4 years, azathioprine suppressed flare incidence and steroid consumption in both diseases (P < 0.001). While in CD discontinuation after 3-4 years did not lead to reactivation, this was the case in UC. However, continuation beyond 4 years further improved clinical activity in CD and steroid requirement in both diseases (P < 0.001). Discontinuation of azathioprine may thus be considered after 3-4 years in CD patients in complete remission without steroid requirement. In all other CD patients and for UC patients in general, continuation seems beneficial. These results support a novel differential algorithm for long-term azathioprine therapy in IBD.